thisdrug what a medicine's name tells you

WHO naming stem · suffix · 15 listed names

-gliflozin

This page was written with AI.

sodium glucose co-transporter inhibitors, phlorizin derivatives

WHO's definition, quoted as written in the 2024 stem book

6 of 15 names appear in these lists: 6 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country.

Names only. This page is about -gliflozin as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -gliflozin. So the letters gliflozin sit at the end of the name (…gliflozin).

All 15 names WHO lists under -gliflozin

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 6 of 15 names appear in these lists: 6 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. atigliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. bexagliflozin
    US brands: BRENZAVVY
    EU (central) brands: none found
  3. canagliflozin
    US brands: INVOKANA
    in combination: INVOKAMET with metformin; INVOKAMET XR with metformin
    EU (central) brands: Invokana
    in combination: Vokanamet with metformin
  4. dapagliflozin
    US brands: FARXIGA
    in combination: XIGDUO XR with metformin; QTERN (discontinued in FDA listings) with saxagliptin; QTERNMET XR (discontinued in FDA listings) with metformin + saxagliptin
    EU (central) brands: Dapagliflozin Viatris, Edistride, Forxiga
    in combination: Ebymect with metformin; Qtern with saxagliptin; Xigduo with metformin; Qtrilmet (withdrawn) with metformin + saxagliptin
  5. empagliflozin
    US brands: JARDIANCE
    in combination: GLYXAMBI with linagliptin; SYNJARDY with metformin; SYNJARDY XR with metformin; TRIJARDY XR with linagliptin + metformin
    EU (central) brands: Jardiance
    in combination: Glyxambi with linagliptin; Synjardy with metformin
  6. ertugliflozin
    US brands: STEGLATRO
    in combination: SEGLUROMET with metformin; STEGLUJAN with sitagliptin
    EU (central) brands: Steglatro
    in combination: Segluromet with metformin; Steglujan with sitagliptin
  7. ipragliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  8. licogliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. luseogliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. mizagliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  11. remogliflozin etabonate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. sergliflozin etabonate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. sotagliflozin
    US brands: INPEFA
    EU (central) brands: Zynquista (withdrawn)
  14. tofogliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. velagliflozin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

atigliflozin

Listed INNCarries 2 WHO stems, most specific first: -gliflozin …

  • -gliflozinend of the nameWHO lists it hereWHO definition: sodium glucose co-transporter inhibitors, phlorizin derivatives
  • gliinside the nameWHO lists it hereWHO definition: antihyperglycaemics

“atigliflozin” is an INN that WHO lists under -gliflozin, gli in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -gliflozin (Part II B) and the 15 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy